Combo Therapy Boosts Survival in Resectable Biliary Tract Cancer

(MedPage Today) — Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival outcomes in patients with resectable biliary tract cancers (extrahepatic cholangiocarcinoma [EHC] and…